

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equip T suspension for injection

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 2 ml dose contains:

**Active substance:**

Immunopurified Tetanus Toxoid  $\geq 30$  IU/ml\*

\* IU: International units

**Adjuvant:**

Aluminium phosphate

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>
Phosphate buffered saline

Clear liquid suspension above a whitish/grey sediment which resuspends readily on shaking.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Horses.

#### **3.2 Indications for use for each target species**

For the active immunisation of horses of 5 months of age or older against tetanus to prevent mortality.

Onset of immunity: within 2 weeks of completion of the primary course

Duration of immunity: 3 years.

#### **3.3 Contraindications**

None.

#### **3.4 Special warnings**

Vaccinate healthy animals only.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

The efficacy of active immunisation of young foals against equine influenza will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal etc. The vaccine should not be used in foals below 5 months of age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.

In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the ability of the animal to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

The product should be administered by respecting appropriate (aseptic) injection technique.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

#### Other precautions:

Not applicable.

### 3.6 Adverse events

Horses.

Rare (1 to 10 animals / 10,000 animals treated):	Injection site swelling <sup>1,3</sup> Stiffness <sup>1</sup> Elevated temperature <sup>1,2</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site pain Hypersensitivity reaction <sup>4</sup>

<sup>1</sup> This condition normally resolves by the day following vaccination.

<sup>2</sup> Mild, transient, typically 9-12 hours post vaccination.

<sup>3</sup> Local, small (10-20 mm in diameter), soft, non-painful.

<sup>4</sup> In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy:

The vaccine may be used in pregnant mares which have been vaccinated against tetanus before pregnancy.

Heavily pregnant mares should not be subject to undue stress when vaccinated.

### **3.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### **3.9 Administration routes and dosage**

**Dose:** 2 ml.

**Administration:** Equip T should be shaken thoroughly before use and administered by deep intramuscular injection.

#### **Primary vaccination**

Two injections of 2 ml with an interval of 4-6 weeks between them.

#### **Booster vaccination**

One dose 36 months after the primary course, repeated at intervals of up to 36 months.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Accidental overdosage is unlikely to cause any reactions other than those described in section 3.6.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI05AB03**

Equip T stimulates active immunity against tetanus.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

### **5.3 Special precautions for storage**

Store in a refrigerator (2 °C - 8 °C).

Protect from light.

Do not freeze.

Keep the container in the outer carton.

### **5.4 Nature and composition of immediate packaging**

Type I glass vial with chlorobutyl rubber stopper and aluminium overseal.

Packaging: Box of 10 single-dose vials. Each box contains 10 sterile disposable 2 ml syringes and 10 sterile needles.

Type I glass syringe closed with bromobutyl rubber plunger stopper and tip cap.

Packaging: Box of 10 single-dose prefilled syringes with needles

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited

## **7. MARKETING AUTHORISATION NUMBER**

Vm 42058/5232

## **8. DATE OF FIRST AUTHORISATION**

17 October 2005

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

December 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*  
Approved: 11 December 2025